Patents are often granted to methods of treatment for diseases and conditions which can be divided into a variety of subclasses based upon disease sub-type, biological target sub-type, patient sub-population, and the like. Logically, diseases and conditions having subclasses and sub-types can be thought of in terms of genus-species (or genus-subgenus). However,...
A Proposal to Address the U.S. Patent “Thicket” Problem During Examination
A so-called patent “thicket” is a collection of many patents with overlapping claims, usually from the same patent application family, covering a single product (and its variations). The use of patent “thickets” to protect drugs and biological products has been the subject of Congressional oversight into rising drug prices.1 As explained below,...
Capuano IP Launches New Website
Salem, MA (Law Firm Newswire) May 03, 2022 – Capuano IP announced today that its new website, CapuanoIP.com, has been launched. Founded in 2020, the firm is a micro-boutique intellectual property practice that provides expert IP and litigation services to clients in the chemistry, pharmaceutical, and related life sciences.
Alnylam Pharms, Inc. v. Dicerna Pharms, Inc. (15-04126-EPL) (Mass. Sup. Ct.)
Represented Dicerna in trade secret litigation regarding RNA interference technology. Settled before trial favorably for Dicerna.
Dicerna Pharms, Inc. v. Alnylam Pharms, Inc. (17-11466) (D. Mass)
Represented Dicerna in antitrust litigation with its competitor Alnylam in the RNA interference field. Settled favorably for Dicerna.
Almirall, LLC v. Acrux DDS Pty. Ltd. (2:2021-cv-11948) (D. NJ)
Representing Defendant Acrux in patent litigation over ANDA to make a generic version of Almirall’s topical acne product Aczone (dapsone). Pending.